MEDISEARCHER NEWS
European Union · Cardiovascular medicine · 14 November 2026
In brief
- The European Medicines Agency’s (EMA) medicines committee has recommended Baxfendy (baxdrostat) for adults whose high blood pressure remains insufficiently controlled despite at least two blood-pressure medicines.
- The positive opinion was adopted on 12 November 2026 and published on 13 November.
- Baxfendy belongs to a new class of medicines called aldosterone synthase inhibitors.
- In the Phase 3 BaxHTN trial, the 2 mg dose reduced systolic blood pressure by an additional 9.8 mmHg compared with placebo after 12 weeks, when added to existing treatment.
- A second Phase 3 trial, Bax24, demonstrated a 14.0 mmHg placebo-adjusted reduction in average 24-hour systolic blood pressure.
- The most common side effect identified by the EMA is hyperkalaemia, meaning elevated potassium levels in the blood.
- Baxfendy is not yet authorised in the EU. European Commission approval and subsequent national access arrangements are still required.
A new type of blood-pressure medicine has moved closer to availability in Europe after the European Medicines Agency recommended Baxfendy (baxdrostat) for adults whose hypertension remains uncontrolled despite treatment with other medicines.
On 12 November 2026, the EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending EU marketing authorisation for Baxfendy. The recommendation was published the following day.
Developed by AstraZeneca, baxdrostat works differently from many established hypertension treatments. It inhibits the production of aldosterone, a hormone that helps regulate salt and water balance and can contribute to persistently elevated blood pressure.
The recommendation is supported by two Phase 3 clinical trials showing significant reductions in blood pressure when baxdrostat was added to existing treatment.
However, the decision is not yet a final European authorisation. Patients in EU countries cannot assume that Baxfendy is already available through their local pharmacy or healthcare system.
What is Baxfendy (baxdrostat)?
Baxfendy is the proposed European brand name for baxdrostat, an oral medicine designed to treat high blood pressure that remains insufficiently controlled with other treatments.
The EMA’s positive opinion covers adults with arterial hypertension whose blood pressure remains inadequately controlled despite taking at least two antihypertensive medicines.
According to the EMA, Baxfendy is expected to be available as film-coated tablets in two strengths:
- 1 mg baxdrostat
- 2 mg baxdrostat
Baxdrostat is a selective inhibitor of aldosterone synthase, an enzyme involved in producing the hormone aldosterone.
If the European Commission grants marketing authorisation, Baxfendy would introduce a new aldosterone synthase inhibitor treatment option into the EU hypertension market.
The medicine is intended for patients who need additional blood-pressure control, not as an automatic replacement for established first-line hypertension medicines.
How does Baxfendy lower blood pressure?
To understand how Baxfendy works, it helps to understand the role of aldosterone.
Aldosterone is a hormone produced by the adrenal glands. It helps regulate how much sodium, water and potassium the body retains or eliminates.
When aldosterone activity is excessive or contributes to poorly controlled blood pressure, it can promote sodium and water retention. This increases blood volume and can contribute to hypertension.
Aldosterone also has effects on blood vessels and other tissues, potentially contributing to inflammation and fibrosis.
Baxdrostat targets the enzyme responsible for producing aldosterone, reducing the amount of the hormone made by the body.
This differs from medicines such as spironolactone, which block the action of aldosterone at its receptor rather than directly inhibiting its production.
Both approaches act on the aldosterone pathway, but through different mechanisms.
The distinction is scientifically important. However, a different mechanism does not automatically mean that baxdrostat is more effective or safer than established treatments. Direct comparative evidence is needed to determine its relative advantages.
What did the Phase 3 BaxHTN trial show?
The main evidence supporting Baxfendy includes the BaxHTN Phase 3 trial, published in the New England Journal of Medicine.
The trial enrolled 796 adults with uncontrolled or resistant hypertension.
Participants were already receiving background blood-pressure treatment. They were randomly assigned to receive:
- Baxdrostat 1 mg once daily;
- Baxdrostat 2 mg once daily; or
- Placebo once daily.
The primary comparison examined changes in seated systolic blood pressure after 12 weeks.
Systolic blood pressure is the upper number in a blood-pressure reading, representing pressure in the arteries when the heart contracts.
BaxHTN results after 12 weeks
| Treatment | Reduction from baseline | Additional reduction versus placebo |
|---|---|---|
| Baxdrostat 2 mg | 15.7 mmHg | 9.8 mmHg |
| Baxdrostat 1 mg | 14.5 mmHg | 8.7 mmHg |
| Placebo | Approximately 5.8 mmHg | Reference group |
Results are based on changes in mean seated systolic blood pressure at week 12. The placebo-adjusted values represent the additional blood-pressure reduction associated with baxdrostat beyond the placebo group, alongside background treatment.
Both baxdrostat doses produced statistically significant improvements compared with placebo.
For the 2 mg dose, the placebo-adjusted reduction was 9.8 mmHg, with a 95% confidence interval from 7.0 to 12.6 mmHg of additional lowering.
The results provide relatively mature evidence that baxdrostat can improve blood-pressure control in patients who remain hypertensive despite existing medicines.
However, the trial’s primary outcome was blood-pressure reduction. It was not designed to establish that baxdrostat directly prevents a particular number of heart attacks, strokes or deaths.
What did the Bax24 trial show?
A second Phase 3 study, Bax24, examined baxdrostat in patients with resistant hypertension.
Unlike a conventional clinic blood-pressure reading, this trial evaluated average systolic blood pressure over a full 24-hour period using ambulatory monitoring.
Ambulatory blood-pressure monitoring records readings at intervals while a person continues normal daily activities and sleeps.
This can provide additional information about blood-pressure control outside the clinic, including overnight and early-morning readings.
At 12 weeks, patients receiving baxdrostat 2 mg alongside existing treatment experienced:
- An average 16.6 mmHg reduction from baseline in 24-hour ambulatory systolic blood pressure.
- An additional 14.0 mmHg reduction compared with placebo.
- Statistically significant blood-pressure lowering throughout the 24-hour monitoring period.
The findings were published in The Lancet.
The BaxHTN and Bax24 results should not be directly compared as though they measured identical outcomes. BaxHTN’s principal endpoint involved seated blood-pressure measurements, whereas Bax24 examined average ambulatory blood pressure over 24 hours.
Together, the studies support the EMA committee’s conclusion that baxdrostat provides clinically relevant blood-pressure lowering in the proposed patient population.
Why is uncontrolled hypertension a major medical problem?
High blood pressure is one of the most important modifiable risk factors for cardiovascular disease.
Over time, persistent hypertension can damage blood vessels and increase the risk of:
- Heart attack;
- Stroke;
- Heart failure;
- Chronic kidney disease; and
- Other cardiovascular complications.
Many patients achieve adequate blood-pressure control through lifestyle changes and established medicines.
However, some people continue to have elevated readings despite taking multiple treatments.
These patients may have uncontrolled or resistant hypertension, although the definitions depend on the number and types of medicines being used, whether the doses are appropriate, and whether elevated readings have been confirmed outside the clinic.
Potential reasons for persistent hypertension include inadequate treatment, difficulty adhering to a complex regimen, high sodium intake, obesity, kidney disease, secondary causes of hypertension and physiological mechanisms involving aldosterone.
A new treatment that addresses aldosterone production may therefore offer an additional option for some patients whose blood pressure remains above target.
How is Baxfendy different from spironolactone?
Spironolactone is an established medicine frequently used as an additional treatment in resistant hypertension.
It works by blocking mineralocorticoid receptors, reducing the effects of aldosterone.
Baxdrostat instead inhibits aldosterone synthase, reducing aldosterone production itself.
| Feature | Baxfendy (baxdrostat) | Spironolactone |
|---|---|---|
| Mechanism | Inhibits aldosterone production | Blocks aldosterone receptors |
| Medicine class | Aldosterone synthase inhibitor | Mineralocorticoid receptor antagonist |
| Clinical status in the EU | Positive EMA committee opinion; final authorisation pending | Established authorised medicine |
| Role in hypertension | Proposed additional treatment for insufficiently controlled hypertension | Established treatment option, including in resistant hypertension |
| Potassium-related concern | Hyperkalaemia is a recognised adverse effect | Hyperkalaemia is also a recognised adverse effect |
The two medicines should not be considered interchangeable simply because they affect the same hormonal pathway.
Importantly, the pivotal baxdrostat studies compared the medicine with placebo on top of background treatment. They do not establish that Baxfendy is superior to spironolactone in a direct head-to-head comparison.
Clinical guidelines, treatment suitability, side effects, kidney function, potassium levels and eventual pricing will all matter when determining how Baxfendy fits into European hypertension care.
What are the side effects of Baxfendy?
The EMA identifies hyperkalaemia as the most common side effect of baxdrostat.
Hyperkalaemia means that potassium levels in the blood are higher than normal.
Potassium is essential for normal nerve, muscle and heart function. However, excessively elevated levels can interfere with the heart’s electrical activity and may become dangerous.
Some people with elevated potassium experience no obvious symptoms. When symptoms occur, they may include muscle weakness, fatigue, palpitations or other disturbances.
Because baxdrostat reduces aldosterone production, its effects on potassium balance are an important consideration.
Patients receiving medicines that affect the aldosterone pathway may require monitoring of potassium levels and kidney function, depending on their treatment regimen and medical circumstances.
Both pivotal Phase 3 trials reported a generally tolerable safety profile, but longer-term experience and post-authorisation monitoring remain important.
The EMA’s detailed European prescribing information, including the full adverse-reaction profile, contraindications and monitoring instructions, is expected to be published after the European Commission grants marketing authorisation.
Patients should not use the trial findings to make independent changes to their existing blood-pressure medicines.
Does Baxfendy prevent heart attacks or strokes?
Lowering elevated blood pressure is an established strategy for reducing cardiovascular risk.
Large bodies of clinical evidence show that effective blood-pressure management can reduce the likelihood of cardiovascular events over time.
However, it is important to distinguish this general evidence from the specific clinical findings for baxdrostat.
The BaxHTN and Bax24 trials demonstrated reductions in blood pressure. They did not directly establish that Baxfendy reduces heart attacks, strokes, cardiovascular deaths or progression to kidney failure.
These outcomes require appropriately designed studies with sufficient follow-up and clinical events.
Therefore, while the observed blood-pressure reductions are clinically encouraging, it would be premature to describe Baxfendy as proven to prevent a specific percentage of cardiovascular events.
Is Baxfendy already approved in Europe?
No. As of 14 November 2026, Baxfendy has received a positive CHMP opinion but not final European Commission marketing authorisation.
The distinction matters because the EMA’s CHMP provides a scientific recommendation, while the European Commission makes the legally binding decision on EU marketing authorisation.
The regulatory process can be summarised as follows:
- CHMP scientific assessment: Completed, with a positive opinion adopted on 12 November 2026.
- European Commission decision: Pending as of 14 November 2026.
- EU marketing authorisation: Would follow a positive Commission decision.
- National launch and patient access: Subject to commercial launch plans, national pricing and reimbursement arrangements, and healthcare-system requirements.
Even after a medicine receives EU-wide marketing authorisation, it may not become immediately available or reimbursed in every member state.
Patients should therefore distinguish between European regulatory approval, pharmacy availability and public healthcare reimbursement.
When will Baxfendy be available in Germany, France, Italy and other EU countries?
There is currently no confirmed EU-wide pharmacy launch date for Baxfendy.
If the European Commission grants authorisation, availability will depend partly on decisions taken within individual countries.
| Country or region | What happens after EU authorisation? |
|---|---|
| Germany | Market launch and statutory health-insurance arrangements will depend on the applicable German regulatory, pricing and reimbursement processes. |
| France | National assessment, pricing and reimbursement decisions will influence patient access through the French healthcare system. |
| Italy | Pricing and reimbursement arrangements involving AIFA will be relevant to access through the Italian health service. |
| Spain | National pricing and financing decisions will influence public-system availability. |
| Netherlands | National reimbursement assessment and insurer arrangements may affect patient access. |
| Ireland | National reimbursement and health-service decisions will determine whether and how eligible patients can obtain subsidised treatment. |
| Sweden and other Nordic EU countries | National pricing, reimbursement and prescribing arrangements will influence availability. |
| Poland | National reimbursement and pricing decisions will determine access through publicly funded treatment arrangements. |
| Malta | Local procurement, formulary and reimbursement decisions will determine whether the medicine becomes available through public services. |
This table describes potential national access pathways, not confirmed launch dates or reimbursement approvals. No country-specific Baxfendy reimbursement decision is implied.
European Commission authorisation would be an important milestone, but it would not guarantee immediate access in every country.
Is Baxfendy approved in the United States?
Baxdrostat has already received US approval for adults whose hypertension is inadequately controlled with other therapies.
However, US regulatory authorisation does not automatically establish availability, prescribing conditions or reimbursement in Europe.
Patients should consult the regulatory information applicable to their own country rather than assuming that US product status or prescribing instructions apply within the EU.
How much will Baxfendy cost in Europe?
No confirmed EU-wide price or national reimbursement schedule was available at the time of publication.
Prices may differ between European countries because medicines are subject to different national pricing, reimbursement and procurement arrangements.
Whether Baxfendy is covered by a public health system, requires a patient contribution or is initially available only through particular prescribing pathways will depend on future decisions.
Patients should be cautious about treating US prices or estimates from other markets as reliable indications of what Baxfendy will cost in Europe.
Who might eventually benefit from Baxfendy?
The proposed European indication focuses on adults whose hypertension remains insufficiently controlled despite at least two blood-pressure medicines.
Potential candidates may include people who:
- Continue to have elevated blood pressure despite an appropriate multidrug treatment regimen;
- Have confirmed uncontrolled hypertension after assessment of medication adherence and blood-pressure measurements;
- Require additional treatment because their current medicines are not achieving the intended blood-pressure target; or
- Have clinical circumstances in which a prescriber considers aldosterone-targeted treatment appropriate.
However, not everyone with hypertension will need or be suitable for baxdrostat.
Before adding another medicine, clinicians may assess factors such as adherence, measurement technique, secondary causes of hypertension, kidney function, potassium levels and the adequacy of existing treatment.
The precise place of Baxfendy in European treatment pathways will become clearer as final prescribing information, clinical guidance and real-world evidence develop.
Frequently asked questions
What is Baxfendy used for?
Baxfendy (baxdrostat) has been recommended by the EMA’s CHMP for adults with arterial hypertension that remains insufficiently controlled despite at least two blood-pressure medicines. Final EU authorisation is pending.
How does baxdrostat work?
Baxdrostat inhibits aldosterone synthase, an enzyme involved in producing aldosterone. Reducing aldosterone production can lower blood pressure by affecting sodium and water balance and other aldosterone-related mechanisms.
How effective is Baxfendy?
In the Phase 3 BaxHTN trial, baxdrostat 2 mg produced an additional 9.8 mmHg reduction in seated systolic blood pressure compared with placebo after 12 weeks, when added to existing treatment. A separate Phase 3 trial demonstrated significant reductions in 24-hour ambulatory blood pressure.
Is Baxfendy better than spironolactone?
There is not sufficient direct comparative evidence to conclude that Baxfendy is superior to spironolactone. The pivotal baxdrostat trials demonstrated benefit compared with placebo alongside background treatment, rather than superiority over spironolactone.
What is the main side effect of Baxfendy?
The EMA identifies hyperkalaemia, or elevated blood potassium, as the most common side effect. The final European product information will provide detailed prescribing precautions and monitoring recommendations.
Is Baxfendy available in European pharmacies?
Not on the basis of the November 2026 CHMP recommendation alone. Final European Commission marketing authorisation is still pending, and national launch and reimbursement arrangements will follow separately.
Does Baxfendy cure high blood pressure?
No. Baxfendy is being developed as a treatment to improve blood-pressure control. The available clinical trials do not demonstrate a permanent cure for hypertension.
Can patients replace their current blood-pressure medicines with Baxfendy?
Patients should not change or stop prescribed treatment based on this announcement. The proposed indication concerns insufficiently controlled hypertension, and clinical trials evaluated baxdrostat alongside existing medicines. Treatment decisions require individual medical assessment.
What happens next?
The next major milestone is the European Commission’s decision on whether to grant Baxfendy marketing authorisation.
If approved, the EMA will publish the detailed European product information, including the authorised indication, dosing instructions, contraindications and adverse-reaction guidance.
Subsequent national pricing, reimbursement and launch decisions will determine how quickly patients in individual European countries can obtain the medicine.
For patients whose blood pressure remains difficult to control despite multiple medicines, Baxfendy represents a potentially important addition to the available treatment options.
Its Phase 3 evidence supports meaningful blood-pressure lowering, but its eventual role will depend on longer-term safety data, comparisons with established treatments and real-world access.
Reviewed by: Dr Mattias Hagman, PhD
Editorial review: MediSearcher reviewed the EMA’s November 2026 CHMP recommendation, Baxfendy regulatory information and the published Phase 3 BaxHTN and Bax24 findings. Blood-pressure outcomes are distinguished from proven cardiovascular-event reductions, and the difference between EU regulatory recommendation, authorisation and national patient access is explicitly identified.
Last reviewed: 14 November 2026
Sources and verification
- European Medicines Agency: Baxfendy regulatory overview and positive CHMP opinion — primary source for the proposed indication, mechanism, formulation, safety information and regulatory status.
- European Medicines Agency: CHMP meeting highlights, 9–12 November 2026 — confirmation of the November recommendation.
- AstraZeneca: Baxdrostat Phase 3 BaxHTN results and regulatory development — trial design, numerical efficacy results and development context.
- ClinicalTrials.gov: BaxHTN Phase 3 clinical trial — trial registration and study details.
- ClinicalTrials.gov: Bax24 clinical trial — trial registration and study details.
This article is provided for general informational purposes and does not replace medical advice. Hypertension treatment should be supervised by an appropriate healthcare professional. Baxfendy’s European regulatory status, prescribing information, pricing and availability may change following future decisions.